Analytical Data
-
Gene name
GALM
- Application
-
Alternative Names
GALM;Galactose mutarotase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96C23
-
Expression Region
1-342aa
-
AA Sequence
MGSSHHHHHHSSGLVPRGSHMASVTRAVFGELPSGGGTVEKFQLQSDLLR VDIISWGCTITALEVKDRQGRASDVVLGFAELEGYLQKQPYFGAVIGRVA NRIAKGTFKVDGKEYHLAINKEPNSLHGGVRGFDKVLWTPRVLSNGVQFS RISPDGEEGYPGELKVWVTYTLDGGELIVNYRAQASQATPVNLTNHSYFN LAGQASPNINDHEVTIEADTYLPVDETLIPTGEVAPVQGTAFDLRKPVEL GKHLQDFHLNGFDHNFCLKGSKEKHFCARVHHAASGRVLEVYTTQPGVQF YTGNFLDGTLKGKNGAVYPKHSGFCLETQNWPDAVNQPRFPPVLLRPGEE YDHTTWFKFSVA
-
Molecular Weight
40 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GALM (Galactose-1-phosphate uridylyltransferase and galactose-4-epimerase) is an essential enzyme complex involved in the metabolism of galactose, specifically in the conversion of galactose-1-phosphate to UDP-galactose. Congenital disorders of galactose metabolism, particularly galactosemia, arise from deficiencies in these enzymes, leading to severe clinical manifestations such as liver damage, kidney complications, and neurological impairment if left untreated. Research on GALM recombinant proteins has gained traction as scientists seek to understand the structure-function relationships and regulatory mechanisms involved in its enzymatic activity. These studies provide insights into critical aspects of galactose metabolism and potential therapeutic strategies for managing metabolic disorders related to galactose. Advances in techniques such as protein engineering and structural biology enable researchers to produce and characterize GALM variants, facilitating a deeper understanding of its role in metabolic pathways and offering new avenues for enzyme replacement therapies. By elucidating the molecular intricacies of GALM, researchers aim to pave the way for innovative treatments and interventions to improve the quality of life for individuals affected by galactose-related metabolic disorders.
